摘要
目的分析糖尿病肾病患者中达格列净的临床效果。方法选取2022年3月-2023年6月延边大学附属医院收治的100例糖尿病肾病患者为研究对象,采用随机数表法分为两组,各50例。两组患者均使用肾衰宁颗粒,对照组结合二甲双胍,研究组结合达格列净。比较两组肾功能、血糖水平、不良反应发生率及生活质量。结果治疗后,研究组肾功能优于对照组,血糖指标水平低于对照组,生活质量评分高于对照组,差异有统计学意义(P均<0.05)。两组不良事件发生率对比,差异无统计学意义(P>0.05)。结论达格列净治疗糖尿病肾病患者,能降低患者血糖水平,提高肾功能,且不会增加不良反应,有助于提高患者生活质量。
Objective To analyze the clinical effect of dapagliflozin in patients with diabetic nephropathy.Methods A total of one hundred diabetic nephropathy patients admitted to the Affiliated Hospital of Yanbian University from March 2022 to June 2023 were selected as the study objects and divided into two groups with fifty cases each by ran-dom number table method.Both groups were treated with Shenshuaining granules,the control group combined with metformin and the study group combined with dapagliflozin.Renal function,blood glucose level,incidence of adverse reactions and quality of life were compared between the two groups.Results After treatment,the renal function of the study group was better than that of the control group,the blood glucose index level was lower than that of the control group,and the quality of score life was higher than that of the control group,and the differences were statistically sig-nificant(all P<0.05).There was no significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion Dapagliflozin in the treatment of diabetic nephropathy patients,can reduce the blood glucose level of patients,improve kidney function,and does not increase adverse reactions,help to improve the quality of life of pa-tients.
作者
石栎蓉
姜涛
李灿
SHI Yuerong;JIANG Tao;LI Can(Department of Nephrology,the Affiliated Hospital of Yanbian University,Yanji 133000,Jilin,China;Department of Endocrinology,Jilin Oilfield Hospital,Songyuan 138000,Jilin,China)
出处
《糖尿病新世界》
2024年第8期180-183,共4页
Diabetes New World Magazine
关键词
达格列净
糖尿病肾病
肾功能
血糖
不良事件
Dapagliflozin
Diabetic nephropathy
Kidney function
Blood glucose
Adverse event
作者简介
石栎蓉(1997-),女,硕士在读,医师,研究方向为肾病学;通信作者:李灿(1965-),男,朝鲜族,博士,主任医师,研究方向为肾病学,E-mail:lican@ybu.edu.cn。
